Neurodegenerative Disease Market Size & Outlook, 2026-2034

Neurodegenerative Disease Market Overview

The global neurodegenerative disease market size is valued at USD 59.06 billion in 2025 and is estimated to reach USD 109.73 billion by 2034, growing at a CAGR of 7.10% during the forecast period. The market value is expected to be impacted by increasing drug approvals by affluent regulatory authorities such as United States FDA to bring effective and affordable treatment alternatives for patients. In addition, integration of artificial intelligence algorithms into drug development, intended to improve efficacy and streamline the drug development process is another factor contributing to market growth.

Key Trends and Insights

• North America contributed more than 42% of the market share in 2025.
• Asia Pacific is estimated to witness the fastest CAGR between 2026 and 2034.
• By Disease Indication, Alzheimer's Disease (AD) segment has held the largest market share in 2025.
• By Drug Type, Immunomodulators segment is expected to expand at the fastest CAGR over the projected period.
• By Routes of Administration, Oral delivery segment held the dominant position in 2025.

Market Revenue Figures

• 2025 Market Size: USD 59.06 billion
• 2034 Projected Market Size: USD 88.74 billion
• CAGR (2026-2034): 7.10%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The neurology market encompasses the full ecosystem dedicated to diagnosing, treating, and managing disorders of the nervous system. This includes a wide spectrum of conditions, from well-known neurodegenerative diseases such as Alzheimer's and Parkinson's to neurovascular disorders like stroke, as well as rare and complex pathologies involving the brain, spinal cord, and peripheral nerves. As neurological conditions continue to rise worldwide, the market plays an increasingly central role in developing next-generation treatments, advancing early detection, and improving long-term care for patients and caregivers.

Latest Market Trends

Escalating Disease Burden Among Ageing Populations

Global ageing is reshaping the neurology landscape. Alzheimer's incidence almost doubles every five years after age 65, placing immense pressure on healthcare systems in the U.S., Europe, Japan, South Korea, and Canada. Governments are integrating dementia action plans into national health strategies, expanding reimbursement for biomarker testing and early diagnostic pathways. Pharmaceutical companies are also adapting, shifting their clinical trial designs toward populations with mild cognitive impairment (MCI) and pre-symptomatic cohorts. This transition not only widens the potential treatment window but also expands the market for emerging disease-modifying therapies.

Advancements in Neuroimaging and Biomarker Diagnostics

The field is shifting away from invasive cerebrospinal fluid tests and expensive PET imaging toward blood-based biomarkers, including plasma Aβ42/40 ratios, phosphorylated tau isoforms (p-tau181, p-tau217), and emerging α-synuclein assays, which enable easier screening in primary care and population-level programs. At the same time, multimodal diagnostic platforms combining blood biomarkers, neuroimaging, digital assessments, and genetic risk profiling are enhancing diagnostic precision. These tools are pushing neurology closer to proactive, rather than reactive, disease management.

To get more insights about this report Download Free Sample Report

Market Driver

Growing Awareness and Advocacy

Public awareness and patient advocacy are driving the neurodegenerative disease market. Many global organisations and community groups are expanding their education campaigns, promoting early symptom recognition, and advocating for increased investment in research and support services. Policymakers are responding to this by providing expanded funding, updated care guidelines, and enhanced reimbursement for diagnostics and specialised treatment pathways. As understanding of neurodegenerative conditions deepens across the public and clinical spheres, earlier diagnosis and higher care uptake are likely to accelerate market growth.

Market Restraint

High Failure Rates in NDD Drug Development

Neurodegenerative disease drug development remains one of the most challenging areas in healthcare. High trial dropout rates are often attributed to adverse effects, slow disease progression, difficulties in measuring clinical endpoints, and the lack of reliable biomarkers for certain conditions. Trials usually span many years, driving up the costs and discouraging investment from pharmaceutical companies. Additionally, regulatory agencies, aiming to ensure patient safety, increasingly require expanded datasets, longer follow-up periods, and evidence across diverse patient groups. Together, these scientific and regulatory hurdles lengthen development timelines and limit the number of candidates that reach approval.

Market Opportunity

Rising Demand for Disease-Modifying Therapies

Most current treatments offer only symptomatic relief, leaving a significant unmet need for therapies that can slow or halt disease progression. Advances in delivery technologies including viral vectors, nanoparticle technologies, and intranasal platforms are making it more feasible to target deep brain regions and previously inaccessible neural pathways. As more health systems recognise the long-term economic benefits of slowing disease progression, reimbursement frameworks are becoming more supportive of innovative therapies. Companies developing true disease-modifying treatments are therefore positioned to capture significant value in the rapidly expanding market segment.

Regional Analysis

North America holds the largest revenue share of 42%, due to its high prevalence, a well-established healthcare system, and a strong commitment to R&D. Drug development leaders are in the United States, with Biogen (Alzheimer's), AbbVie (Parkinson's), and Ionis Pharmaceuticals (ALS) leading the innovation front. Other aspects of the region that promote growth include the upside in easy-to-access reimbursement from publicly funded insurance (Medicare) and private insurers, as well as an increasing ageing population. North America also conducts significantly more clinical trials for screening and drugs for neurodegenerative disease therapies than other regions, which reduces the time to approval.

• The U.S. benefits from robust regulatory frameworks, including accelerated approval pathways for breakthrough therapies, as well as comprehensive reimbursement policies that support early diagnosis and disease-modifying treatments. Widespread awareness campaigns, well-established patient advocacy groups, and extensive clinical trial networks further strengthen its market position. As a result, the U.S. remains the largest revenue contributor in the region, particularly for therapies related to Alzheimer's and Parkinson's diseases, as well as for emerging biomarker-based diagnostics and advanced gene and RNA therapies.

Asia Pacific Market Insights

Asia-Pacific is witnessing fastest growth in the neurodegenerative disease market, driven by increasing awareness, rising healthcare expenditure, and a growing elderly population. Countries such as China and Japan are driving this growth, supported by government initiatives aimed at enhancing healthcare access and advancing treatment options. The presence of both local and international companies, including Amgen and AbbVie, fosters a dynamic environment for innovation and collaboration in the region.

• Japan is the leading country in the Asia-Pacific (APAC) neurodegenerative disease market, driven by its rapidly ageing population, advanced healthcare infrastructure, and strong government focus on dementia and neurodegenerative disorders. The country has implemented comprehensive national dementia strategies, including support for early diagnosis, biomarker screening, and access to disease-modifying therapies.

Europe Market Insights

Europe is the second-largest market for neurodegenerative diseases. The region is characterised by a strong regulatory framework that encourages innovation and ensures patient safety. Initiatives from the European Medicines Agency (EMA) promote research and development, particularly in countries like Germany and France, which are leading in market growth and adoption of new therapies. Germany, France, and the UK are at the forefront, with a competitive landscape featuring major players like Roche and Novartis. The European market is also witnessing increased collaboration between pharmaceutical companies and research institutions, enhancing the development of novel treatments.

• Germany in the neurodegenerative disease market is supported by its advanced healthcare system, strong pharmaceutical and biotechnology sectors, and proactive government initiatives addressing dementia and neurodegenerative disorders. Germany also hosts numerous clinical trials and research collaborations, particularly in Alzheimer's and Parkinson's disease, attracting investment in innovative therapies, including biologics, gene therapies, and disease-modifying treatments.

Middle East and Africa Market Insights

The Middle East and Africa represent an emerging market for neurodegenerative diseases, currently accounting for approximately 10% of the global market share. The region faces challenges, including limited healthcare infrastructure and awareness, but there is a growing demand for effective treatments. Government initiatives aimed at enhancing healthcare access and increasing funding for research are expected to drive market growth in the coming years. Countries such as South Africa and the UAE are leading the way in adopting new therapies and enhancing patient care.

• Saudi Arabia has launched national health initiatives aimed at improving diagnosis, treatment, and long-term care for neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Rising public awareness, expanding access to advanced diagnostics, and the adoption of modern therapies are fueling market growth. Additionally, partnerships with international pharmaceutical companies and investment in clinical research are strengthening Saudi Arabia's position as the largest revenue contributor in the MEA region for neurodegenerative disease therapeutics and diagnostic services.

Latin America Market Insights

The neurodegenerative disease market in Latin America is steadily expanding, driven by an ageing population, rising disease awareness, and improved access to healthcare services across major countries, including Brazil, Mexico, Argentina, and Chile. Governments in LATAM are progressively integrating dementia and neurodegenerative disorders into public-health strategies, which is enhancing early detection efforts and encouraging the use of biomarker testing.

• Brazil is driven by its large and ageing population, expanding healthcare infrastructure, and growing national focus on neurological disorders such as Alzheimer's and Parkinson's disease. The country has made significant strides in improving access to diagnostic services, including cognitive assessments and advanced imaging, while public and private healthcare providers are increasingly adopting biomarker-based screening tools.

Disease Indication Insights

Alzheimer's Disease (AD) has the largest market share in neurodegenerative diseases, based primarily on the extent of its burden, with dementia being the most prevalent and common form, and the rapid growth of the aged population across the world. New disease-modifying therapies have driven revolutionary market expansion by targeting the root causes of diseases, rather than just their symptoms. The growing burden of disease receives continuous research and development support, which drives advancements in drug development and diagnostic technology.

Multiple sclerosis is projected to see robust growth during the forecast period. In the U.S., nearly 1 million people live with MS, and global prevalence stands at approximately 2.9 million. This rising incidence is fueling R&D activity, with new immunomodulatory and remyelination-focused therapies advancing through the pipeline. Increasing diagnostic rates and expanding awareness further support sustained market expansion.

Drug Type Insights

Immunomodulators held a dominant market share in the year 2025, as they provide very effective therapy options for a variety of autoimmune and neurodegenerative illnesses. Furthermore, the growing presence of important companies is likely to raise patient and physician awareness of the benefits of immunomodulators. As they strive to obtain a competitive advantage in the market, they are developing novel immunomodulators to treat a variety of chronic conditions.

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors is estimated to be the fastest-growing, with a CAGR of 13.3% over the forecast period of 2026-2034. It is owing to an increase in the number of patients with bipolar diseases, schizophrenia, Huntington's disease and other neuropsychiatric disorders undergoing long-term medical treatments with antipsychotic medication.

Routes of Administration Insights

Oral delivery remains the dominant route for neurodegenerative disease therapies due to its convenience, patient compliance, and suitability for chronic treatment regimens. Most symptomatic treatments, including dopaminergic agents for Parkinson's and cholinesterase inhibitors for Alzheimer's, are administered orally. The segment continues to expand as novel small-molecule drugs and emerging oral disease-modifying compounds enter clinical trials.

Intravenous (IV) delivery is the fastest-growing route of administration in the neurodegenerative disease market, primarily used for biologics, monoclonal antibodies, and emerging gene or enzyme therapies that require systemic circulation or direct access to the central nervous system. IV administration allows precise dosing, rapid onset of action, and controlled delivery of complex molecules that cannot be absorbed orally.

Competitive Landscape

The market is moderately concentrated, with major global players leveraging strong patent portfolios, broad distribution networks, and extensive R&D capabilities. Biogen, Roche, Eisai, and Novartis together control about 62% of branded revenue, though ample room remains for emerging biotech firms. Strategic alliances continue to shape the market. Overall, the market is defined by active collaboration, selective consolidation, and increasing convergence across pharmaceuticals, biotech, diagnostics, and advanced therapeutic platforms.

List of key players in Neurodegenerative Disease Market

1. Amneal Pharmaceuticals Inc
2. Hoffmann-La Roche
3. Boehringer Ingelheim International GmbHF
4. Merck & Co. Inc.
5. Novartis AG
6. Pfizer Inc.
7. Teva Pharmaceuticals Ltd
8. UCB SA
9. Biogen Inc
10. Acadia Pharmaceuticals Inc.
11. Neuronity Therapeutics, Inc.
12. Arkuda Therapeutics Inc
13. NeuroX1 Inc.
14. Annovis Bio, Inc.

To get more findings about this report Download Market Share

Strategic Initiatives

• May 2025 - Sanofi announced an agreement to acquire Vigil Neuroscience, a clinical-stage biotech focused on neurodegenerative diseases. The acquisition brings Vigil’s investigational oral small-molecule TREM2 agonist, VG-3927, intended for Alzheimer’s disease, into Sanofi’s neurology pipeline.
• May 2025 - FDA granted clearance to Lumipulse, the first blood test for Alzheimer’s disease that detects plasma amyloid-β and p-tau biomarkers, allowing for easier, less invasive screening for patients aged 55+ with cognitive symptoms.
• April 2025 - At the AD/PD 2025 International Conference, Roche revealed data from its Phase Ib/IIa “Brainshuttle™” study of Trontinemab, showing dose-dependent, rapid clearance of amyloid plaques in the brain of Alzheimer’s patients.